Answers are grounded in this paper and cite their sources.
Prospective trial showed filgrastim biosimilar matched original in improving neutropenia in gynecological cancer patients.
Few clinical studies have compared the efficacy of a filgrastim biosimilar with that of the original filgrastim in gynecological cancer. This study compared the efficacy of a filgrastim biosimilar to that of the original filgrastim for treating neutropenia that developed following chemotherapy for gynecological cancer. Forty gynecological cancer patients undergoing chemotherapy were enrolled in this study. Efficacy was evaluated by the recovery of the absolute neutrophil count following administration of filgrastim biosimilar or original filgrastim in patients who developed neutropenia after undergoing chemotherapy. The incidence of febrile neutropenia (FN) was also evaluated. The neutrophil count after filgrastim biosimilar administration showed a change similar to that observed with the original filgrastim. The incidence of FN was the same for both drugs. Filgrastim biosimilar had similar efficacy to that of original filgrastim in patients who developed neutropenia following chemotherapy for gynecological cancer.
No takes yet. Share an insight, caveat, or question.
Sato et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: